Diazepam prodrug stabilizes human aminopeptidase B during lyophilization.
Human aminopeptidase B (APB) is a hydrolytic zinc metalloenzyme currently being investigated as a biocatalyst for intranasal delivery of prodrug/enzyme combinations. APB is known to be unstable in solution, with significant degradation over the course of 24 hr at room temperature. Therefore, enzyme stability is a major concern to ensure a viable drug product. Lyophilization is one technique commonly used to increase the activation energy for denaturization of proteins and confer an extended shelf-life. However, the lyophilization process itself can cause conformational changes and aggregation, leading to inactivation of the enzyme. In this study, we demonstrate the use of the substrate avizafone (AVF), a prodrug for diazepam, as a stabilizer to minimize inactivation of APB during lyophilization. Permutations of APB samples combined with AVF, trehalose, and/or mannitol were snap frozen and lyophilized at 0.016 mbar and 24 °C for 18 hr. The lyophilizates were then reconstituted in pH 7.4 PBS at 32 °C to measure the activity of APB. Of the permutations, an APB+AVF+trehalose combination resulted in minimum degradation with 71% retention of activity. This was followed by APB+AVF and APB+trehalose with 60% and 56% retention of activity respectively. In comparison, APB+mannitol and APB alone retained only 16% and 6.4% activity. Lyophilizates of the APB+AVF+trehalose formulation were subjected to a 6-month accelerated stability study, at the end of which negligible reduction in activity was observed. These results suggest co-lyophilization of an enzyme with its substrate can impart stability on par with the commonly used lyoprotectant, trehalose, but the combination of substrate and trehalose provides a greater stabilizing effect than either additive alone.